Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer

Lin, Lingyun; Yang, Li; Zeng, Qiang; Wang, Lin; Chen, Mao-Li; Zhao, Zehang; Ye, Guodong; Luo, Qin; Lv, Pei-Yu; Guo, Qiwei; Li, Boan; Cai, Jun; Cai, Wangyu

doi:10.1186/s12943-018-0834-9

Cited by 187 publications

(132 citation statements)

References 16 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…The plasma exosomal Sox2ot expression is high in PDAC patients and correlated with TNM stage and overall survival 43 . LncUEGC1 is confirmed to be remarkably upregulated in plasma exosomes of early stage gastric cancer (EGC) patients and has better diagnostic accuracy to discriminate EGC patients from healthy individuals and those with premalignant chronic atrophic gastritis than carcinoembryonic antigen (CEA) 46 . We showed that UFC1 was highly expressed in exosomes from NSCLC cells and serum of NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression

et al. 2020

View full text Add to dashboard Cite

Long non-coding RNAs (LncRNAs) have been suggested as important regulators of cancer development and progression in non-small cell lung cancer (NSCLC). Nevertheless, the biological roles and clinical significance of lncRNA UFC1 in NSCLC remain unclear. We detected the expression of UFC1 in tumor tissues, serum, and serum exosomes of NSCLC patients by qRT-PCR. Gene overexpression or silencing were used to examine the biological roles of UFC1 in NSCLC. RNA immunoprecipitation and ChIP assays were performed to evaluate the interaction between UFC1 and enhancer of zeste homolog 2 (EZH2) and the binding of EZH2 to PTEN gene promoter. Rescue study was used to access the importance of PTEN regulation by UFC1 in NSCLC progression. UFC1 expression was upregulated in tumor tissues, serum, and serum exosomes of NSCLC patients and high level of UFC1 was associated with tumor infiltration. UFC1 knockdown inhibited NSCLC cell proliferation, migration and invasion while promoted cell cycle arrest and apoptosis. UFC1 overexpression led to the opposite effects. Mechanistically, UFC1 bound to EZH2 and mediated its accumulation at the promoter region of PTEN gene, resulting in the trimethylation of H3K27 and the inhibition of PTEN expression. UFC1 knockdown inhibited NSCLC growth in mouse xenograft tumor models while the simultaneous depletion of PTEN reversed this effect. NSCLC cells derived exosomes could promote NSCLC cell proliferation, migration and invasion through the transfer of UFC1. Moreover, Exosome-transmitted UFC1 promotes NSCLC progression by inhibiting PTEN expression via EZH2-mediated epigenetic silencing. Exosome-mediated transmit of UFC1 may represent a new mechanism for NSCLC progression and provide a potential marker for NSCLC diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interestingly, cancer-derived lncRNAs can be packaged into exosomes and transported in circulating blood, which makes exosomal lncRNAs as an ideal noninvasive diagnostic and prognostic biomarker for cancer detection [21]. From recent studies, Lin et al demonstrated that plasma exosomal lncRNA UEGC1 originating from gastric cancer cells was highly sensitive to the early stage of gastric cancer [22]. Moreover, Sedlarikova et al reported that serum exosomal lncRNA PRINS could act as a diagnostic biomarker in multiple myeloma [23].…”

Section: Ivyspringmentioning

confidence: 99%

Exploration of Serum Exosomal LncRNA TBILA and AGAP2-AS1 as Promising Biomarkers for Diagnosis of Non-Small Cell Lung Cancer

Yao¹,

Tang²,

Yang³

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Non-small cell lung cancer is the most common type of cancer with a poor prognosis, and development of an effective diagnostic method is urgently needed. Exosomal lncRNAs, a class of transcripts longer than 200 nucleotides packaged into exosomes, have been defined as an ideal diagnostic biomarker for cancer. However, little is known about the clinical utility of exosomal lncRNAs in NSCLC. Here, we aimed to identify exosomal lncRNAs as promising biomarkers for NSCLC diagnosis. First, serum exosomes from NSCLC patients were successfully isolated by a polymer precipitation kit and then identified by TEM, NTA and western blot analysis. A total of nine candidate lncRNAs were detected by qRT-PCR in a training set. The two exosomal lncRNA TBILA and AGAP2-AS1 were screened out for the higher levels in NSCLC patients than that of healthy controls in a validation set. And there was a significant positive correlation between these exosomal lncRNAs levels and tumor size, lymph node metastasis and TNM stage. Additionally, we validated that these exosomal lncRNAs were stable in serum. Next, we evaluated the diagnostic efficiency of exosomal lncRNAs in NSCLC patients by ROC curve analysis. The data showed that individual TBILA or AGAP2-AS1 exhibited better diagnostic efficiency in NSCLC patients with different tumor pathologic subtypes and early stage, whereas the combination of lncRNAs did not provide better results than individual lncRNAs. Notably, the combination of two exosomal lncRNAs and the serum tumor biomarker Cyfra21-1 widely used in clinical practices further improved the diagnostic accuracy for NSCLC patients. This study suggests that exosomal lncRNA TBILA and AGAP2-AS1 may be promising biomarkers for diagnosis of NSCLC.

show abstract

“…Moreover, several studies have indicated that serum exosomal lncRNAs show increased expression in several human cancers, including colorectal cancer, hepatocellular carcinoma, and gastric cancer. [10][11][12][13] Emerging evidence indicates H19 is an oncogene. 14 The H19 gene encodes a 2.3-kb lncRNA, which is located on human chromosome 11p15.5 and exclusively expressed from the maternal allele.…”

Section: Introductionmentioning

confidence: 99%

<p>Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Breast Cancer Diagnosis</p>

Zhong¹,

Wang²,

Li³

et al. 2020

OTT

View full text Add to dashboard Cite

Purpose: There is an urgent need for new biomarkers for the diagnosis of breast cancer. Exosomes can communicate with cells through transport molecules, including long-chain noncoding RNA (lncRNA), which is considered as a promising noninvasive biomarker. Here, we aimed to determine the potential of long noncoding RNA (lncRNA) H19 in the circulating exosomes for the diagnosis of breast cancer (BC). Materials and Methods: We measured the levels of lncRNA H19 in serum-derived exosomes from patients with breast cancer (BC) or benign breast disease (BBD) and healthy subjects, using quantitative real-time PCR. H19 levels were also measured for pre-operative and post-operative patients. Receiver operating characteristic curve was constructed, and the area under the curve (AUC) was calculated to determine the applicability of exosomal H19 levels as biomarkers in BC. The relationship between H19 relative expression and clinical features of BC patients was also analyzed. Results: Exosomal H19 expression levels were upregulated in patients with BC compared to that in patients with BBD and healthy controls (BC vs BBD, P < 0.001; BC vs healthy subjects, P < 0.001). The median serum exosomal H19 levels were significantly lower in post-operative than that in the pre-operative patients (P < 0.001). The AUC for exosomal H19 analysis was 0.870 (95% CI: 0.774-0.966) with a sensitivity of 87.0% and specificity of 70.6%, which was higher than the AUCs for CA15-3 and CEA, ie, 0.822 and 0.811, respectively. Moreover, exosomal H19 expression levels were associated with lymph node metastasis (P = 0.039), distant metastasis (P = 0.008), TNM stages (P = 0.022), ER (P=0.009), PR (P = 0.018), and Her-2 (P = 0.021). Conclusion: Our results indicated that serum exosomal H19 acts as a novel biomarker for the diagnosis of BC.

show abstract

Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer

Cited by 187 publications

References 16 publications

Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression

Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression

Exploration of Serum Exosomal LncRNA TBILA and AGAP2-AS1 as Promising Biomarkers for Diagnosis of Non-Small Cell Lung Cancer

<p>Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Breast Cancer Diagnosis</p>

Contact Info

Product

Resources

About